Greetings, and welcome to the Avadel Pharmaceuticals’ Fourth Quarter Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief Question-and-Answer Session will follow the formal presentation. Please note that we will be taking one question and one follow-up question per person.

[Operators Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Mr. Tom McHugh, Chief Financial Officer of Avadel. Thank you, Mr. McHugh. You may begin. .

Thank you and good morning and thank you for joining us on our conference call. This morning, we issued our fourth quarter and year-end financial results news release and this release can be found on our website at www.avadel.com.

As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements.

These risks include risk that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements; uncertainties regarding market acceptance of products; and the impact of competitive products and pricing.

These and other risks are described more fully in Avadel's public filings under the Exchange Act including the Form 10-K for the year ended December 31, 2018.

Except as required by law, Avadel undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise. On the call with me today are Greg Divis, our Chief Executive Officer; and Dr. Jordan Dubow, our Chief Medical Officer.

And at this time, I will turn the call over to Greg..

Thank you, Tom. Good morning everyone, and thank you for joining us on our fourth quarter 2019 conference call. I'll start with an update on our business, the substantial progress we have made and our critical near-term milestones as we continue the execution of our strategic objectives and the transformation of Avadel.

I'll then turn the call over to Jordan to give an update on FT218, followed by Tom, who will review the financials for the quarter. I will end the call with a few closing comments and we will conclude with a Q&A session. With that, let’s get started.

The Avadel team has made tremendous progress delivering on the key objectives that we set out at the beginning of 2019. This included a significant restructuring and the acceleration of our FT218 program. Both of which has been executed exceptionally well.

This performance is a direct result of strengthening our critical organizational capabilities, especially in the areas of clinical, medical and technical operations.

The momentum we have created for our company continued in the first quarter of 2020 with the recently completed $65 million private capital raise with a group of leading biotech investors. This capital raise is another validation of both the strategy and the execution our team has delivered over the last twelve months.

As a result of this raise, we now have even more flexibility to accelerate our development plans for FT218, while significantly extending our cash runway.

We believe these highly regarded biotech investors taking a meaningful position in Avadel sends a strong message to the broader market about the progress of our FT218 program and this management team’s ability to execute and collectively transform Avadel.

These actions have put us on an accelerated path towards recognizing the growth and value creation opportunity we believe FT218 may provide as we look to disrupt the approximately $1.7 billion sodium oxybate market.

With the last patient, last visit in the REST-ON trial being just two weeks away and the company is subsequently reporting top-line results of the trial in Q2.

We have already set in motion the next steps for the critical and commercial development of FT218 in order to effectively and efficiently prepare FT218 for the market, as well as prepare the market for FT218. We are truly excited about the potential of our proprietary, once-nightly extended release formulation of sodium oxybate.

To-date, the feedback we have received shows strong interest in FT218 from across the narcolepsy community. We believe that interest is centered around the number of potential benefits associated with its once-nightly dosing regimen. That concludes my FT218 comments.

I want to take a minute to address certain questions we routinely receive about intellectual property and our freedom to operate in this space. First and foremost, let me be clear. Although FT218 contains the same drug substance as the referenced twice-nightly sodium oxybate, it is a different drug product that will have a different label.

We are not an ANDA. We are an NDA being filed under a 505(b)(2) pathway and as such our label does not and will not match that of the reference listed drug. For example, FT218 will have its own clinical efficacy and safety data. Its own clinical [Audio Disconnect].

Ladies and gentlemen, we have temporarily lost connection with our speakers. Please continue to hold. Ladies and gentlemen, thank you for your patience. We are now reconnected. Please continue..

Thank you, and our apologies to everyone. We had a slight technical glitch here. But we are back on and should be good. So, I think we understand where we cut-off. So, I’ll go back and start on my conclusion of FT218 comments as it relates to questions, we routinely receive about intellectual property and our freedom to operate in this space.

First and foremost, although FT218 contains the same drug substance as the referenced twice-nightly sodium oxybate, it is a different drug product that will have a different label. We are not an ANDA. We are an NDA being filed under a 505(b)(2) pathway and as such our label does not and will not match that of the reference listed drug.

For example, FT218 will have its own clinical efficacy and safety data. Its own clinical pharmacology including specific drug, drug interaction data and its own dosage and administration sections in its label. Furthermore, one should not assume our strategy to advance this program was developed in isolation.

We have sought out and received expert advice from leading regulatory and legal advisors, not to mention the FDA itself as sources for guidance and feedbacks on our overall strategy.

We are keenly aware of the Orange Book listed patents of the referenced twice-nightly products and believe we have a path based on the clearly stated regulations to get FT218 to market quickly.

While we won’t go into the specifics on this call, as we have stated numerous times, we believe there is a clinical or a data generation strategy that will inform our labeling and our regulatory strategy and take into consideration all relevant Orange Book listed patents.

Our primary objective is to take the necessary actions to bring an FDA approved, FT218 to patients as soon as we possibly can and we believe our clinical development, regulatory and legal plan is designed to support that strategy specifically.

We believe we are putting ourselves in the best possible position based on the relevant regulations and our FT218-specific data that we have generated, all of which we have done while considering the guidance and feedback of leading experts and the FDA itself. Now, a few comments about our base hospital business.

Strategically, this business is all about cash flow generation that we use to support the development of FT218 with gross margins net of any royalties of 50% to 55% on the three current commercial products, in 2019 generated over $25 million of free cash flow. Tom will cover more specifics on these products during his financial review.

However, we remain very pleased with how this current portfolio continues to perform in the phase of competition and pricing pressures. I will conclude my opening comment today with these final thoughts.

First, the strategic moves taken by the company over the last twelve months have transformed Avadel, while allowing us to begin to rebuild trust and confidence with investors that we can deliver long-term shareholder value. Number two, we look forward to reporting our top-line data readout for our pivotal REST-ON trial in Q2.

Number three, we are well positioned from a liquidity standpoint to move forward towards an FDA approval and expand our market development and preparation works for FT218, and our Board, management and employees are committed to doing what is in the best interest of the patients we serve and maximizing value for our shareholders.

This is the culmination of the activities I just touched on which includes simplifying and focusing our business strategy, strengthening our management and R&D teams, significantly reducing our cost structure, executing FDA agreed strategic changes to our FT218 development program, which reduce the time to REST-ON completion by twelve months and optimizing the cash flow from our hospital business to further support our FT218 development.

To-date, our proven ability to execute on our strategy has been recognized and validated by both new and existing shareholders and supported by the expansion of coverage – covering research analysts, which is greatly appreciated by me, our entire management team and our Board of Directors.

We take our responsibility seriously to execute and build real intrinsic shareholder value and are grateful for the support of all stakeholders and the execution of our team over the last twelve months. I’ll now turn the call over to Dr. Jordan Dubow, our Chief Medical Officer to provide an update on the FT218 development program.

Jordan?.

Thank you, Greg, and good morning, everyone. We are in an exciting point in the development of FT218 with only two patients left in the REST-ON Phase 3 study in the last patient, last visit set to occur within the next two weeks.

Let me repeat, we have only two patients left in our pivotal REST-ON Phase 3 study in the last patient, last visit set to occur within the next two weeks. This puts us on track to announce the top-line data from the study in the second quarter.

As we have discussed previously, based on the pharmacokinetic data that we presented last year for FT218, we think our pharmacokinetic profile should translate into clinical efficacy.

As a reminder, we demonstrated that FT218 at the 4.5 gram and 6 gram dose strength had the same exposure with a lower overall Cmax compared to twice-nightly sodium oxybate in lower plasma concentrations eight hours after dosing.

We believe the PK profile of our investigational FT218 could potentially allow for patients to achieve a deep, consolidated sleep with sleep architecture matching that of a normal sleeper without narcolepsy while avoiding a second nightly dose and the associated consequences that come with it.

As we get closer to the readout of our top-line data, we believe FT218 will demonstrate robust, clinically meaningful and highly significant improvements in excessive daytime sleepiness and cataplexy compared to placebo as has been previously seen with sodium oxybate, the only approved drug in the U.S.

for both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

As a reminder, it was just this past September that we announced the FDA’s agreement to an amendment to the protocol and a statistical analysis plan for the REST-ON Phase 3 pivotal study and then that study would remain under a special protocol assessment agreement with the FDA.

Most importantly, we were able to implement this amendment while retaining the scientific, statistical, and clinical robustness of the study.

As a result of this amendment, we needed to recruit 205 patients in the study instead of the originally planned 264, which we achieved and then exceeded in December with the final enrollment of our 212 patients.

With enrollment completed, we have been able to reduce the timeline to report data from the REST-ON study by up to 12 months from the original proposed timelines prior to the amendment to the study in September.

Looking ahead, we recently announced that we are initiating an open-label extension study for REST-ON and a switch study to evaluate patients switching from twice-nightly sodium oxybate to once-nightly FT218.

Although these studies are not new for a regulatory submission or approval, we felt it is important to provide those patients who participate in the REST-ON study with continued access to FT218 during the review and approval process, as well to generate data for physicians and patients switching from twice-nightly sodium oxybate to once-nightly FT218.

We expect the first patient to be enrolled in this study by the end of Q1 2020. We think the clinical data we have generated or in the process of gathering for FT218 will service a strong basis for a complete regulatory package, as well as position FT218 as a potentially disruptive new therapy in the narcolepsy market.

Additionally, as we look to the next quarter in presenting our top-line data for REST-ON, we will also be presenting four posters on pharmacokinetic data of FT218 at the upcoming American Academy of Neurology Meeting.

Some of this data was previously presented at the World Sleep Meeting last year, but we will also be presenting new data regarding the association between adverse events and the pharmacokinetics of sodium oxybate.

I want to again thank all the patients, investigators and study staff who have participated or are currently participating in the REST-ON study, as well as the Avadel team for getting us to this exciting and pivotal time for the company and for the patients we serve.

With that, I would like to turn the call over to our CFO, Tom McHugh to review the financials. .

Thanks, Jordan. I will review a few financial highlights for the fourth quarter. We announced earlier today the sales from our three current commercial products have continued to outperform expectations with total revenue of $11 million for the fourth quarter and $59 million for the full year 2019.

Fourth quarter revenues were down $20.9 million in the fourth quarter in 2018, which is due to a combination of lower volume and lower net selling prices across our hospital products as a result of increased market competition. Looking ahead, we are currently projecting revenue for the first quarter of 2020 to be at or above $10 million.

And finally, with respect to revenue, just a brief update on Nouress, our fourth hospital product for which we received FDA approval in December, as well as associated intellectual property. While we are making preparations for a potential commercial launch, we are not prepared to provide any timing regarding launch guidance for Nouress at this time.

As we have publicly stated, our patent infringement suit – a patent infringement suit was filed against us in Delaware relating to this matter, but we have not yet been formally served notice of the suit. As such, we are not obligated to respond unless we choose to proactively.

We think it is safe to assume this sort of action is a leading indicator to parties that wish to try to resolve this matter outside of litigation. And now a few comments regarding operating expenses. Our R&D expense was $7.8 million and the increase versus the prior year was primarily the result of our R&D spend on the clinical development of FT218.

Selling, general and administrative expense was $7.7 million in the fourth quarter and the decline versus the prior year is primarily due to cost reductions associated with the divestiture of Noctiva and lower operating expenses resulting from cost reduction actions implemented as part of our commitment to preserve cash.

We recorded $1.8 million of restructuring charges in the fourth quarter of 2019, mostly related to the closure of our operations in France. We have completed most of the restructuring activities that commenced in early 2019, and as a result of that restructuring, we reduced our annual operating expenses by over $80 million.

The company’s net cash use in the fourth quarter was $8.2 million, which include a royalty payment of $2.7 million related to our hospital products business with the remainder attributable primarily to recurring operations.

Our cash at the end of December was $64.2 million, compared to $99.9 million at December 31st, 2018 and cash at the end of 2019 does not include the $65 million in gross proceeds from the private placement, which we completed in early February with several leading biotech investment bonds.

On the completion of that private placement, we had approximately $121 million of cash on hand.

And based on current cash on hand, continued cash flow generation from our hospital products business and our current clinical development plan for FT218, we have significantly extended our cash runway and the financial flexibility to support the acceleration of the FT218 program. And now, I will turn the call back over to Greg. .

Thanks, Tom. In closing, we are very pleased with the progress made over the past twelve months and especially since last spring with the addition of new management, followed by the key changes to our pivotal Phase 3 REST-ON study.

The key driver behind the execution of our different initiatives and programs is attributable to the Avadel team including to a large part those of our team that joined us this past year.

We are now down to two remaining patients and less than two weeks away from the last patient, last visit in the REST-ON study, which as we stated, we currently expect will allow us to announce top-line data in the second quarter.

The momentum we’ve established has continued in 2020 with our recent additional new leading biotech investors via our $65 million private capital raise and although the change in progress has been positive it is only the beginning and we recognize that today is the new baseline against which we will be measured.

We had to remain fully committed to executing the necessary strategic plans that we believe can build sustainable shareholder value. I do want to thank our investigators, our patients, our shareholders, and our fellow employees for all of their contributions to our progress and support of our strategy, and of course, our Board of Directors.

We look forward to providing investors and all stakeholders with further updates in the future and especially our upcoming Q2 2020 top-line data readout for our Phase 3 REST-ON trial. With that, I believe we are ready to open the line for Q&A and operator, I’ll turn it over to you. .

[Operator Instructions] Your first question comes from Matt Kaplan with Ladenburg Thalmann. Please go ahead. .

Hi, guys. Congrats on the progress and thanks for taking the questions. Just wanted to focus in a little bit on FT218, given the near-term readout of data there expected.

Can you give us a sense in terms of how you think FT218 can differentiate from Xyrem in terms of clinical profile?.

Hey, Matt. It’s Jordan. Thanks for the question.

Yes, so, I think, as we have discussed previously, our Phase 3 study is a comparison to placebo and so, the purpose of our study to show the effectiveness of our treatment strategy and doing so versus placebo, I think when we – we’ve talked before and I’ve talked with many of you on the phone, there are severe drawbacks to making cross-study comparisons.

That being said, those are made. And so, I think, what we are really looking at is focusing on having, as I said, highly significant clinically meaningful and robust data.

I think some of the things based on our PK profile, we are very excited about is, the lower Cmax that we’ve talked about, there is some data to suggest that should result in lower rates of adverse events. And, as I said, having one dose and what we think will lead to more consolidated sleep, we think it can have advantage as well.

So, from the REST-ON study itself, obviously, all of our data is going to be compared to placebo. We are excited to see our safety data and see what that looks like and we have good expectations that there would be differentiated – differentiation there based on the PK data we have. .

That’s helpful.

And then, in terms of additional clinical data that you think you should generate beyond the REST-ON data to perhaps further differentiate FT218 in the marketplace or are there plans that you have to execute some of those studies?.

Yes, one of them obviously was being the extension study which, again, the main purpose was to provide continued access to drug but also generate some long-term data that we think will be helpful for us and obviously the switch data will be important, that’s to commence, we will be designed it in a certain way it could get useful information from that study as well.

Outside of that, we obviously have a strategy and other things that we can do to position the drug and where we think we have differentiation. Right now the focus will be getting the data on the NDA as quickly as we can, but we are evaluating all studies and looking at other things that we can do to help differentiate the product. .

Yes, and Matt, it’s Greg, I’ll just add a comment. I think that, this most recent capital raise just gives us additional flexibility and optionality in this regard that we had to had in the past and allows us to really think about how we can treat and build value around FT218 between now, up to and through and past approval. .

Your next question comes from David Amsellem with Piper Sandler. Please go ahead. David, your line is live. You might have yourself muted. .

Hi. Sorry.

Can you guys hear me?.

Yes, we can. Thanks, David. .

Okay.

So, just real quick on 218, what are your thoughts philosophically on where pricing in the oxybate market is going to head with you in the market and with low sodium oxybate and eventually authorized generics and then vanilla generics? Can you talk about the trajectory of pricing and the extent to which there could be price destruction over the next several years? And where you fit in, in that pricing continuum? And then, secondly, you may not want to provide specifics on your thinking regarding whether or not there will be litigation with Jazz.

But can you talk about your views on whether there would be a 30-month stays here to the extent that Jazz does initiate litigation. I don’t know if you could speak to that, but if you can, that would be helpful. Thank you. .

Yes. Thanks, David. First, as we think about pricing and not having any visibility to what anyone else will do in the marketplace, we certainly recognize that, over – a little over 15,000 patients or so represents approximately $1.7 billion of revenue.

So, the price per patient is obviously quite expensive running north of $120,000 to $140,000 per patient, per year on average. So, as we think about pricing and then we have done our research with payers and others, as you think about the kind of 2023 through 2025 window, when we are in an authorized generic scenario.

I think the expectation is that you will see some price compression, but obviously not at the same rate as you will when you see multiple generics that likely will come in 2026.

From that standpoint, our view, understanding what Jazz will or won’t do around their low sodium version is that we believe that we have an opportunity to bring a product to market that could be priced appropriately to create excess opportunities for us that between now and if you will, the end of 2025 give us an opportunity to fully position FT218 to rightful place in the marketplace.

Right, so, do we think that in 2026 when more – the broader settlements kick in, that will be additional price compression we do – do we believe that there could be some step edits we do.

But I think it’s fair to say that these products today and even the authorized generic based upon our research are heavily scrutinized relative to prior authorizations, current step edits, quantity limits and medical necessity, right.

So, we don’t see that dramatically changing in the future as this molecule is typically a third-line product for the most part nor do we think polypharmacy in this category is going to change either, and that there will always be a role for sodium oxybate in the marketplace.

It’s our job commercially from an execution standpoint to take share of the sodium oxybate market and that is a 100% our focus both through commercial strategies, market access strategies, distribution and pricing strategies.

As it relates to 30-months stays and litigations and again, we won’t speak as to whether or not Jazz will or won’t litigate, what we can’t speak to generally, David is, just the statute, right.

So, as a 505 (b)(2) as an NDA as we noted in the commentary that our label does not and will not match to that of the reference listed drug twice-nightly sodium oxybate.

We believe based upon the statute that there are options for us to effectively generate data which we’ve already done and we are not going to discuss what that data says, that will inform our labeling strategy as it relates to the relevant Orange Book listed patents.

And if we are successful in essence addressing those Orange Book listed patents in our labeling appropriately per the statute, then, we should find ourselves in a position where required to certify nor Jazz will be in a position or anyone else will be in a position to then enforce a 30-months stay, right, based upon Hatch Waxman.

It doesn’t mean that parties don’t have intellectual property that they choose to assert themselves. However, we feel very confident that if we are successful in our regulatory and clinical and labeling strategies that our probability or likelihood to prevail even outside of Hatch Waxman from a litigation standpoint. We feel very confident in it.

So we – it’s very clear for us the strategy we’ve employed. We’ve got great advice from leading experts and we’ve executed that and we know what our dataset. So, we are pursuing on that path.

But there is no reason for us to disclose that data at this stage and yet we feel we have a clear pathway to effectively address and deal with the Orange Book listed patents. And to be clear, a 30-months stay is not an automatic issue here, because again, we are an NDA.

Our label does not match and will not match and there will be differences around that and we understand how those differences manifest themselves as it relates to their respective Orange Book listed patents. .

Okay. Great. That’s helpful. If I may thinking a follow-up and just in terms of your proposed REMS, can you walk us through to the extent you can how – you believe your REMS on the product would not run a sale of what Jazz is doing in their remaining IP on their REMS program.

How should we think about that?.

Yes. I mean, again, I don’t think we are going to – if you will tip our hand in a meaningful way here from that standpoint. What we do know about their Orange Book listed REMS patent is that, I believe it expires in mid-2023. It expires shortly after the first launches of the authorized generics from that standpoint.

And that – that there has been an alternative, if you will, secondary REMS that has been developed and – by the FDA in conjunction and in counsel with the FDA that allows it to work if you will outside of the REMS program that is in place for the current reference listed drug. So, from our standpoint, there is a roadmap that’s been created, for sure.

And again, we are a different drug product with the same drug substance. So there will be differences in that regard to some of the details around how our REMS and components of our REMS, which will tie directly back to our labeling and our regulatory strategy that we referenced a couple minutes ago.

But we feel with the advisors we have who are fairly knowledgeable in this space and on this matter, we have a clear pathway for us of how we will build the REMS program that won’t infringe Jazz’s intellectual property, which again, as I understand and I believe expires in kind of mid-2023. .

Thank you. Your next question comes from Paul Matthews with Stifel. Please go ahead. .

Great. Thanks very much for taking my questions. As it relates to contextualizing the REST-ON data, obviously, there is a lot of caveats across drop comparisons given how much older desire on studies are and of course, any other baseline differences.

That said, what will you guys be looking at it in the data to garner conviction that 218 is just an efficacious desire? And then, I have a follow-up. Thank you. .

Yes, Paul. Thanks for the question. Yes, I think, as I said previously, we are – what we expect and what we like to see is, highly significant data, clinically robust, clinically meaningful changes on our endpoints, right.

On MWT, there has been ranges in various studies that was twice-nightly sodium oxybate as well as some of the other recent studies, sodium oxybate is highly effective for cataplexy, big improvements in the CGI. So I think, numerically, we expect to see robust, highly significant numbers.

I think if you look at older versus newer studies even with different formulations of sodium oxybate, there are clearly differences in just deltas, if you look at it that way. And so, I think, we expect just to see good numbers on space value, physicians could see the meaningfulness of it.

Obviously, we are doing a switch study as well, which will also show that, we believe patients can switch from the twice-nightly formulation to our once-nightly formulation. .

Great. Thank you.

And then, Greg, maybe can you just talk about given the data are positive, what do you want to accomplish in the rest of 2020 and 2021 as it relates to getting ready to launch the drug and how much of the leg work can be done ahead of time as it relates to establishing infrastructure that can make reimbursement and access a seamless process?.

Yes, great question. Again, I think that, as we think about it, it’s an evolution, right.

And there is a number of different work streams that are important in terms of the preparation of FT218 for the market, whether that be medical affairs, whether that be market access, whether that be distribution and patient support services, whether that be commercial infrastructure build and sales force footprint, so on and so forth.

So, across all of those work streams, I would say that, as we go through data readout through the balance of 2020, and into 2021, all of those will move at different phased from kind of planning, to initial build-out to full build-out, right.

And some of those will be predicated upon not full execution until we have an approval and we are in a 90-day DEA scheduling window. Some of that will happen beforehand as we seek to build-out.

But for us, from our standpoint, we have been in and continue to be in deep planning stages where we then move from planning to beginning to build and execute at certain time periods, kind of key minus NDA submission, key minus NDA approval based upon our assumptions.

And we do agree that things like distribution, market access, medical affairs are all really important work streams that need to advance in a material way as we proceed towards an approval. .

Very good. Thanks very much. .

Yes, thank you, Paul. .

Thank you. Your next question comes from Francois Brisebois with Craig-Hallum. Please go ahead. .

Thanks guys for taking the questions. A couple have been asked or raised. So, thank you for providing a lot on the IP here. I was just wondering in terms of obviously timing here will be very important until the authorized generics come in and then the vanilla generics.

But, can you discuss a little bit, you are getting really close to the end here of this clinical trial.

Any potential impact on, I just have ask about everything that’s happening with this Coronavirus involved with the trials in the U.S., patients coming, patients getting feedback, and then, on that note, just in terms of the switch progress, you are about to start it.

When can we expect readout here and this open-label expansion of switch have any impact on potential launch timing?.

Yes, so, maybe you can address the latter question and I’ll finish up on the Coronavirus, Jordan?.

Yes, so, the open-label extension study is really one that we anticipate running through approval. The switch study we have assessed number of patients that we are looking to enroll that which we haven’t publicly stated yet.

And so, in all likelihood, this – it’s probably going to be a – again, the extension studies through approval, the switch study will be likely shorter than that depending on rates of enrollment. In terms of timelines, anything related to the NDA itself, this study should have no impact on it. It’s not required for submission.

It’s not required for approval. It’s just again more additional data that we think is important for us to generate on FT218 as we look to position it for the market. .

Thanks, Jordan. Franc, and thanks for the question about all that’s going on in the marketplace today. Clearly, it’s – we are very concerned for the well-being of our employees, for the well-being of our patients, our customers, our shareholders, everybody from that standpoint. And obviously, we are very serious about our assessment of this situation.

We have for a number a days and almost a couple weeks now been conducting regular risk assessments across the entirety of our business in some aspects daily and really understanding kind of where we sit and its impact on our programs at large and have put in the appropriate mitigation strategies to the extent that there are things that we can have some control over.

We are very pleased to say that, with really only two patients left to go, which means, we’ve enrolled and completed 210 patients and their last visits with a short window from now, we feel like, we are going to get to completion of this trial and that won’t have any impact on it.

We are obviously in discussions, sometimes daily again with our sites as we clean data, to queries answered and look to move toward a database lock, which we certainly have a certain set of assumptions now. At this stage, we haven’t – we don’t believe that there is any material risk to our timing, at this stage in terms of Q2 data readout.

But it’s something we can’t predict tomorrow or a month from now or a year from now in that regard. So we’ve taken the approach that we are going to manage it daily, basically depending upon which business issue it is and its relative importance to where the company is and what our near-term milestones are.

So we have a very good handle of it and what we are working on. And if there is anything that comes up that changes that, we obviously will want to update everyone else.

But as we sit here today, given where we are on data readout, at this stage in terms of where we are in completion of this – the trial, we don’t see a material shift in the timeline at this stage. .

Okay. Great. Thank you. And then, if I can sneak in one last one here. We talked about data coming. We talked about preparations for a launch.

We talked about IP stuff, I am just wondering a little bit here in terms of timeline, you got the authorized generic and then, come 2026, when the other ones kind of come in, there is a little more pricing pressure debatably.

Can you just discuss a little bit, what your research has showed? Or if we can look at any precedence that kind of make sense where the formulary work just to make sure that patients – there is not necessarily a step edit where everyone that’s on FT218 might have to go back through the two-times nightly generic and then kind of go that way where they could potentially stay on FT218.

And then, but it’s more for the ones that were potentially on Xyrem to get step edit. And just the thoughts behind the formulary play at that time, once the vanilla generics come in? Thank you. .

Yes, I mean, it’s obviously something that we question and have just come off of some research to help think about that now.

And to recognize that we are trying to answer a question that in six years maybe very different in terms of what’s happening in the marketplace and benefit designs and how things have emerged or evolved from a health insurance perspective in our marketplace.

That being said, our feedback kind of at the simplest description would be that that our expectation would be that price would come down and it’s hard to really predict how much at this point, because we are not really sure how many of these eight or nine settlers will actually come into the market, right.

That’s a fairly small patient population overall. There is going to have to be an infrastructure investment around distribution and around REMS. We are just not sure. It’s hard to predict five or six years from now at that – from that standpoint. And that certainly will have some bearing on what happens from a pricing standpoint.

But we do believe when it comes to currently treated patients, based on what we’ve heard today and again it’s 2020, that we don’t envision a scenario where patients will be asked to step away from their current treatments and be shifted back to something else as a process for, if you will, implementing a step edit.

At least as we done research and think about it today.

As you think about new patients, we think it’s pretty unequivocally clear that if pricing comes down in a material way that payers will likely implement some relevant step edit or some demonstration of not – we cannot tolerate or have failed, if you will, and some definition of failure to be determined a twice-nightly generic before allowed to be on a brand.

It’s also one of the reasons why we have every incentive to want to file right and complete and robustly, but as soon as we can to give us as much of a window as we can to really establish FT218’s rightful position in the marketplace before we get to 2026 and based again on the same research project we are coming off of now, the expectation around authorized generic is that, at this stage, we are likely be treated like a brand, right, in terms of its coverage, its restrictions, its step edits or what not that’s currently happening today on the branded twice-nightly formulations.

.

Okay. Great. Thank you so much. And congrats on the progress. .

Yes. Thanks, thanks, Franc, and thanks to everybody for spending some time on the call with us today and having a little patience where we had a slightly technical glitch here early on in the call.

We appreciate everyone’s time and for joining us today and we look forward to providing you updates over the coming weeks on the progress we are making and throughout the balance of 2020. With that, we will end the call and wish everyone a great day. Thanks. Bye-bye. .

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation..